Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept in Europe: An Observational Postauthorisation Study

Trial Profile

Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept in Europe: An Observational Postauthorisation Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Macular degeneration
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 17 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 29 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Jan 2017.
    • 06 Oct 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top